Designing Polymeric Binders for Pharmaceutical Applications
Designing Polymeric Binders for Pharmaceutical Applications
复制标题
DOI：
10.1039/9781849737821-00483
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Leblond, Jeanne
中科院分区：
文献类型：
--
作者：
Bertrand, Nicolas;Colin, Patrick;Leblond, Jeanne
聚合物在生物医学领域的应用由来已久，例如药物输送或组织再生。然而，它们本身作为治疗剂的使用是相对较新的。1美国食品和药物管理局(FDA)于1996年批准了醋酸格拉替拉默(Copaxone)，2或FDA于2006年批准了SPL7013的快速通道指定研究新药(IND)应用，3这是第一种基于树枝状大分子的治疗方法，引起了人们对这些分子独特性质的兴趣。由于它们的高分子量，它们可以被设计成模拟生物大分子。此外，它们是生物疗法的一种有吸引力的替代品，因为它们更容易制造，而且它们的合成结构可以很容易地调整。在精确控制聚合物的合成、功能化和表征方面取得了重大进展，并开辟了聚合物作为药物的新的治疗应用。
Polymers have been used for a long time in biomedical fields such as drug delivery or tissue regeneration. However, their use as therapeutic agents by themselves is relatively recent. 1 The Food and Drug Administration’s (FDA) approval of glatiramer acetate (Copaxones) in 1996, 2 or the FDA’s fast track designation Investigational New Drug (IND) application of SPL7013 in 2006, 3 the first dendrimer-based therapeutic, has attracted the interest on the distinctive properties of these molecules. Due to their high molecular weight, they can be designed to mimic biomacromolecules. In addition, they represent an attractive alternative to biological therapeutics, since they are easier to manufacture and their synthetic structures can be easily tuned. Significant progress has been made on the precise control of polymer synthesis, functionalization and characterization4 and opened new therapeutic applications of polymers as drugs.